ArticleInternational journal of general medicine2026
Association Between Serum MPO-DNA and CCL26 Levels and Poor Prognosis in Children with Multidrug-Resistant Organism-Associated Pneumonia.
Article in International journal of general medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To investigate serum myeloperoxidase-DNA (MPO-DNA) and C-C motif chemokine ligand 26 (CCL26) levels in pediatric multidrug-resistant organism (MDRO)-associated pneumonia and their association with 28-day prognosis. Methods: In this single-center prospective cohort study, 220 pediatric patients hospitalized for MDRO-associated pneumonia (February 2022-February 2025) were enrolled. Serum MPO-DNA, CCL26, C-reactive protein (CRP), and procalcitonin (PCT) were measured by ELISA within 24 h of admission. Patients were classified into good-prognosis (clinical improvement, ≥50% pulmonary lesion absorption, no severe complications) and poor-prognosis (treatment failure, severe complications, or death within 28 days) groups. Multivariable logistic regression and ROC analysis were performed. Results: Of 220 patients, 68 (30.9%) had poor prognosis. The poor-prognosis group showed significantly elevated CRP, PCT, MPO-DNA, and CCL26 (all Conclusion: Elevated serum MPO-DNA and CCL26 levels are associated with 28-day poor prognosis in pediatric MDRO pneumonia. Combined detection shows favorable discriminative performance. However, given the single-center design and lack of external validation, clinical utility requires further multicenter confirmation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.